Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16177792 | 0.89 | SLC22A12 (0.66) | SLC22A12 | |
| SCHEMBL16177778 | 0.88 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL17559553 | 0.88 | SLC22A12 (0.70) | SLC22A12 | |
| SCHEMBL16177504 | 0.88 | SLC22A12 (0.66) | SLC22A12 | |
| SCHEMBL16178025 | 0.85 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL16177548 | 0.85 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL16177908 | 0.84 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL16177417 | 0.84 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL16177658 | 0.83 | SLC22A12 (1.00) | SLC22A12 | |
| SCHEMBL16177612 | 0.83 | SLC22A12 (1.00) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259327-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| US-9067922-B2 | Chemical compounds | PFIZER LIMITED (GB) | 2015-06-30 | — | — | US | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| EP-2590951-B1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| WO-2012004743-A1 | BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010182-A1 | Chemical Compounds | ICAGEN INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SLC22A12 999/4885 |
| US-20120010182-A1 | Chemical Compounds | SCN1A, SCN1B, CACNA1E | SLC22A12 2912/4885 |
| US-20150259327-A1 | Chemical Compounds | SULT2A1, SULT1A1, SULT1E1 | SLC22A12 1128/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SLC22A12 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.